Kostrzewski et al

NAFLD is a spectrum of pathologies ranging from benign hepatic steatosis through to non-alcoholic steatohepatitis (NASH), which can ultimately lead to cirrhosis and liver cancer. There are currently no FDA approved drugs for the treatment of NAFLD/NASH and there is a clear requirement for better models to understand this disease.